Myriad Genetics Blog Myriad Genetics Blog > Myriad Genetics’ Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy Myriad Genetics’ Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy November 28, 2012 Corporate Prostate Cancer SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled “CCP Score Significantly Predicts PSA Failure After EBRT,” was presented on Wednesday, November 28th, 2012 at the Annual Meeting of the Society of Urological Oncology in Bethesda, Maryland. The study demonstrates that the Prolaris® test, which measures cell cycle progression (CCP) genes, significantly predicts PSA biochemical recurrence in patients after treatment with external beam radiation therapy (EBRT). …READ MORE HERE